CSTL logo

Castle Biosciences, Inc. (CSTL)

$35.75

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CSTL

Market cap

$1.09B

EPS

-0.64

P/E ratio

--

Price to sales

2.94

Dividend yield

--

Beta

1.001101

Price on CSTL

Previous close

$35.14

Today's open

$36.03

Day's range

$35.07 - $36.43

52 week range

$17.72 - $44.28

Profile about CSTL

CEO

Derek J. Maetzold

Employees

1002

Headquarters

Friendswood, TX

Exchange

NASDAQ Global Market

Shares outstanding

30549507

Issue type

Common Stock

CSTL industries and sectors

Healthcare

Medical Diagnostics & Screening

News on CSTL

What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call

Castle Biosciences NASDAQ: CSTL raised its full-year revenue outlook after reporting 24% third-quarter revenue growth, driven primarily by demand for its TissueCypher test.

news source

MarketBeat • an hour ago

news preview

Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript

Castle Biosciences, Inc. (CSTL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • 2 hours ago

news preview

Castle Biosciences Reports Third Quarter 2026 Results

Delivered Q3 2026 revenue of $102.9 million, an increase of 24% over Q3 2025 TissueCypher ® test report volume increased 47% over Q3 2025 Raising full-year 2026 revenue guidance to $385-395 million from $365-375 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2026.

news source

PRNewsWire • 7 hours ago

news preview

Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Beats Revenue Estimates

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.02 per share a year ago.

news source

Zacks Investment Research • 5 hours ago

news preview

Castle Biosciences to Participate in Upcoming Investor Conferences

FRIENDSWOOD, Texas, Oct. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Wednesday, Nov. 18, 2026, at 12:30 p.m. Central time.

news source

PRNewsWire • Oct 28, 2026

news preview

Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026

FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.

news source

PRNewsWire • Oct 15, 2026

news preview

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone FRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide additional risk information beyond histopathology to support risk-aligned patient management decisions.

news source

PRNewsWire • Oct 12, 2026

news preview

Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management

Data show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6% Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertain FRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place Sept.

news source

PRNewsWire • Sep 30, 2026

news preview

New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus

FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE).

news source

PRNewsWire • Sep 28, 2026

news preview

New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™

Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacy Among patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatment FRIENDSWOOD, Texas, Sept. 24, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection.

news source

PRNewsWire • Sep 24, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Castle Biosciences, Inc.

Open an M1 investment account to buy and sell Castle Biosciences, Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CSTL on M1